Exagen Inc. (XGN)

NASDAQ: XGN · IEX Real-Time Price · USD
2.23
-0.02 (-0.89%)
Mar 24, 2023, 4:00 PM EDT - Market closed
-0.89%
Market Cap 37.52M
Revenue (ttm) 45.56M
Net Income (ttm) -47.39M
Shares Out 16.83M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,793
Open 2.26
Previous Close 2.25
Day's Range 2.16 - 2.26
52-Week Range 2.04 - 9.20
Beta 1.27
Analysts Buy
Price Target 6.63 (+197.31%)
Earnings Date May 9, 2023

About XGN

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue dis... [Read more]

Sector Healthcare
IPO Date Sep 19, 2019
Employees 219
Stock Exchange NASDAQ
Ticker Symbol XGN
Full Company Profile

Financial Performance

In 2022, Exagen's revenue was $45.56 million, a decrease of -5.66% compared to the previous year's $48.30 million. Losses were -$47.39 million, 76.5% more than in 2021.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for XGN stock is "Buy." The 12-month stock price forecast is $6.63, which is an increase of 197.31% from the latest price.

Price Target
$6.63
(197.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Record AVISE® CTD Volume in 2022 Record AVISE® CTD Volume in 2022

6 days ago - GlobeNewsWire

Exagen Inc. to Participate in Upcoming March Conferences

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following March inve...

3 weeks ago - GlobeNewsWire

Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life ...

1 month ago - GlobeNewsWire

Exagen Inc. Elects Tina S. Nova, Ph.D.

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair...

2 months ago - GlobeNewsWire

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022

SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, aft...

5 months ago - GlobeNewsWire

Exagen Announces Appointment of John Aballi as CEO

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President.  Longtime CEO and President Ron Rocca, who took...

5 months ago - GlobeNewsWire

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chi...

6 months ago - GlobeNewsWire

Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting

SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American Colle...

6 months ago - GlobeNewsWire

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory Univers...

7 months ago - GlobeNewsWire

Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of -41.82% and 25.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to valid...

8 months ago - GlobeNewsWire

Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual Growt...

8 months ago - GlobeNewsWire

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after th...

8 months ago - GlobeNewsWire

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility

SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing enables ...

9 months ago - GlobeNewsWire

Exagen Inc. Expands Coverage with MediNcrease

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC...

10 months ago - GlobeNewsWire

Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth Sto...

10 months ago - GlobeNewsWire

Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered ser...

11 months ago - GlobeNewsWire

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has pr...

11 months ago - GlobeNewsWire

Exagen Inc. Reports First Quarter 2022 Results

Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly Volume in March Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® ...

11 months ago - GlobeNewsWire

Exagen Announces Five-Week Campaign for Lupus Awareness Month

SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a fiv...

11 months ago - GlobeNewsWire

Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022

SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after ...

11 months ago - GlobeNewsWire

Exagen Inc. to Participate in Investor Summit Group's Q2 Conference

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group's Q2 Conference,...

1 year ago - GlobeNewsWire